Citations

Clear

1526 citation(s) found for "Sun, Bo".

Empowering Women in Academic Emergency Medicine: A Time-Efficient Leadership Workshop Incorporating AI-Coaching to Enhance Skills
Mishkin, Hannah, Lema, Penelope C. , Binz, Nikki, Walker, Laura, Platt, Melissa , Sun, Wendy W., Werner, Sandra, Sethuraman, Kinjal , Walker, Laura, Chekijian, Sharon , Linden, Judith A. , Thomas, Ynhi T. , Raukar, Neha P.

Mayo Clinic

No container title available | February 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.17918/00011273 Get It

Dynamic MRI of Fluid and Solute Transportation across the Arachnoid Barrier in the Human Meninges
Li, Yinghao , Sun, Yuanqi, Paez, Adrian , Xu, Gaoqiang , Pillai, Jay J. , Iliff, Jeffrey J., Ganji, Sandeep , Knutsson, Linda, Zijl, Peter C. M. Van, Calabresi, Peter A., Sun, Yuanqi , Knutsson, Linda , Sun, Yang-bai , Sun, Yuanqi , Iliff, Jeffrey , Ganji, Sandeep K , Knutsson, Linda , Calabresi, Peter A , Hua, Jun , Pillai, Jay J , Iliff, Jeffrey J. , Zijl, Peter C.M. van , Kamson, David , Calabresi, Peter A.

Mayo Clinic

Radiology | February 24, 2026 | Volume: 318 | Issue: 2 | Pages: No page available

10.1148/radiol.252393 | PMID 41733473 Get It

Dynamic fluid and solute transportation across the arachnoid barrier in the meninges of healthy participants was measured by tracking intravenous gadolinium-based contrast agent entering cerebrospinal fluid from dural blood vessels using dynamic dual-spin-echo perfusion MRI.
Med-VLM: Enhancing Medical Image Segmentation Accuracy Through Vision-Language Model
Zhao, Yihao, Zhong, Enhao, Yuan, Cuiyun, Li, Yang, Zhao, Man , Li, Chunxia, Hu, Jun, Liu, Wei, Liu, Chaoying

Mayo Clinic

2025 IEEE/CVF International Conference on Computer Vision Workshops (ICCVW) | February 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: 7342-7352

10.1109/iccvw69036.2025.00756 Get It

CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link?
Gava, Flavia , Yates, Bonnie , Sun, Zhouxin, Li, Grace , O'Koren, Chelsea, Adhikari, Biplov , Luger, S. M., Shalabi, Haneen , Mattison, Ryan J. , Türkbey, Evrim , Paietta, Elisabeth , Wang, Hao-Wei, Mullighan, Charles G., Litzow, M., Shah, Nirali N, Turkbey, Evrim B , Yuan, Constance M , Wang, Hao-Wei , Mullighan, Charles G , Litzow, Mark R. , Shah, Nirali N , Yuan, Constance M. , Wang, Hao‐Wei , Mullighan, Charles G. , Silbert, Sara K. , Litzow, Mark R.

Mayo Clinic

Blood Advances | February 18, 2026 | Volume: 10 | Issue: 9 | Pages: 3044-3053

10.1182/bloodadvances.2025018480 | PMID 41707115 Get It

Abstract Cytokine receptor–like factor 2 rearrangement (CRLF2r), an aberration causing a Philadelphia chromosome–like gene expression profile and a poor prognostic marker in B-cell acute lymphoblastic leukemia (B-ALL), endows relative chemotherapeutic resistance. Extramedullary disease (EMD), including both central nervous system (CNS) and non-CNS involvement, can also be associated with worse outcomes. The relationship between CRLF2r and EMD is unknown. Based on an initial observation of patients with relapsed/refractory (R/R) CRLF2r B-ALL and EMD, a single-center retrospective review was conducted to evaluate the incidence of EMD in patients with CRLF2r B-ALL. Across 177 children, adolescents, and young adults with R/R B-ALL, 21 (11.9%) harbored CRLF2r, of whom 19 (90.5%) had EMD at some point during their treatment course. In contrast, only 78 of the 156 patients (50%) without CRLF2r ever had EMD (P = .0003). In the CRLF2r cohort, 8 (38.1%) presented with EMD at diagnosis: 7 with CNS and 1 with non-CNS EMD. At relapse, 17 (80.9%) had EMD: 4 (19%) had CNS EMD, 9 (42.9%) had non-CNS EMD, and 4 (19%) had both. Isolated EMD was observed in 2 patients (11.8%) at first relapse and in 3 (17.6%) with multiple relapses. Given these findings, further study to evaluate this potential association between EMD and CRLF2r in R/R B-ALL is indicated.
Metabolic Heterogeneity and Niche Rewiring in Plasma Cells are Associated with Progression from MGUS to Multiple Myeloma
Walch, A, Zhang, Guoxing, Sun, Na , Chawla, Yogesh , Jevremovic, Dragan, Taro, Hitosugi, Kumar, Shaji, Gonsalves, Wilson, Jevremović, Dragan , Gonsalves, Wilson I. , Jevremovic, Dragan , Kumar, Shaji K , Gonsalves, Wilson , Sun, Na, Chawla, Yogesh , Taro, Hitosugi, Kumar, Shaji , Walch, Axel

Mayo Clinic

No container title available | February 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8795835/v1 | PMID 41756448 Get It

Abstract Progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is driven by coordinated metabolic reprogramming within clonal plasma cells and the bone marrow microenvironment. We applied high-resolution MALDI–FT-ICR mass spectrometry imaging (MSI) to archived FFPE bone-marrow biopsies, integrated with matched bone marrow plasma metabolomics, to map spatial and systemic metabolic alterations. Spatial clustering delineated plasma-cell–rich niches, while Hill-based diversity and β-diversity metrics quantified intra- and inter-compartment heterogeneity. MM niches exhibited elevated 3-hydroxykynurenine, rewired tryptophan–kynurenine flux, and increased nucleotide and bioactive lipid metabolism associated with proliferation. Notably, some MGUS-like samples displayed MM-like metabolic niches undetectable in bone marrow plasma alone, underscoring spatial heterogeneity. Cross-compartment integration revealed conserved metabolic signatures and systemic redistribution of key metabolites, consistent with ecological reorganization and niche divergence during progression. These findings establish spatial metabolomics of biopsies as a framework to dissect intramedullary metabolic heterogeneity and enable metabolite-based risk stratification in plasma-cell disorders.
Abstract PD4-11: Contralateral Breast Cancer Risk in Women with PALB2-Associated Breast Cancer
Metcalfe, Kelly , Stachowski, A , Couch, F. J., Marabelli, Monica , Wong, S. M., Domchek, S. M., Kim, R., Cajal, T. Ramon y, Fruscio, R, Yadav, S., Hoey, C., Karamali, S., Sun, P., Lubinski, J., Narod, S., Pal, T., Eisen, Andrea , Kim, Raymond H. , Metcalfe, Kelly A , Eisen, Andrea , Kim, Raymond H , Couch, F.J., Aeilts, Amber M. , Eisen, Andrew , Hoey, Christianne, Lubiński, Jan

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-11-PD4-11

10.1158/1557-3265.sabcs25-pd4-11 Get It

Abstract Introduction: Women with a germline pathogenic variant (PV) in PALB2 face a lifetime risk of breast cancer, generally exceeding 40%. We have initiated an international clinical follow up study of women with stage 0 to stage 4 breast cancer and a PALB2 PV to evaluate clinical characteristics and to determine optimal treatments. The objective of the current study was to estimate and to identify factors predictive of contralateral breast cancer (CBC) risk. Methods: Clinical data, including diagnostic, treatment, and follow-up data, were collected by medical record review for eligible women with breast cancer and a germline PV in PALB2. PV carriers were followed every two years to collect information about recurrences, new cancers, and vital status. Data was summarized using descriptive statistics. The risk of CBC was estimated by following women from the date of breast cancer diagnosis until the date of: 1) contralateral breast cancer, 2) contralateral mastectomy, 3) death from any cause, or 4) last follow-up. The cumulative incidence of CBC was calculated with the Kaplan-Meier method. Cox proportional hazards regression was used to identify factors associated with contralateral breast cancer risk. Covariates included age at diagnosis, ER status, grade, nodal status, chemotherapy, radiation therapy, tamoxifen, and bilateral salpingo-oophorectomy (time-dependent). Results: Among 888 PALB2 carriers, the mean age at diagnosis of breast cancer was 49.3 years (range 22 to 83 years). Overall, 36 women (4.1%) were diagnosed with synchronous bilateral breast cancer. 73.6% of the breast cancers were ER-positive, and 29% were lymph node-positive. Patients were followed for a mean of 5.6 years (range 0.3 to 22 years) from date of diagnosis. During the follow-up period, 53 patients were diagnosed with a metachronous CBC. The 15-year risk of metachronous CBC was 26.4% overall; 19.5% for those diagnosed younger than 50 years, and 34.8% for those diagnosed at 50 years or older. In a multivariate analysis, ER status was not significantly associated with CBC risk (RR 1.15, 95%CI 0.45-2.93, p=0.77). Bilateral salpingo-oophorectomy (BSO) was associated with a significant reduction in the risk of CBC (RR 0.17, 95%CI 0.04-0.70, p=0.02). In the follow-up period, 47 women were diagnosed with another incident cancer, including seven with pancreatic cancer and three with ovarian cancer Conclusion: The high 15-year risk of contralateral breast cancer suggests that bilateral mastectomy should be considered for primary surgical intervention. Moreover, bilateral salpingo-oophorectomy (BSO) significantly reduces the risk of CBC and should be considered post-treatment. Citation Format: K. Metcalfe, A. Stachowski, F. Couch, M. Marabelli, S. Wong, S. Domchek, A. Aeilts, A. Eisen, R. Kim, T. Ramon y Cajal, R. Fruscio, S. Yadav, C. Hoey, S. Karamali, P. Sun, J. Lubinski, S. Narod, T. Pal. Contralateral Breast Cancer Risk in Women with PALB2-Associated Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-11.
Abstract GS3-01: Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2
Kotsopoulos, J., Seca, M., Jacek, G., Huzarski, T., Møller, P., Kim, R. H., Singer, C. F., Karlan, B., Cajal, T. Ramon y, Pal, Tuya, Bordeleau, Louise , Foulkes, W., Tung, N. M., Couch, F. J., Neuhausen, S., Zakalik, Dana , Cybulski, C., Olopade, O. I., Metcalfe, K., Fruscio, R, Sun, P., Lubinski, J., Narod, S., Eisen, Andrea , Metcalfe, Kelly , Kim, Raymond H. , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Kotsopoulos, Joanne , Seca, Marta , Huzarski, T., Møller, Pål , Kim, R.H., Singer, Christian F. , Karlan, Beth Y. , Aeilts, Amber M. , Pal, Tuya , Eisen, Andrew , Foulkes, William D. , Couch, F.J., Neuhausen, Susan L. , Cybulski, Cezary , Lubiński, Jan

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS3-01-GS3-01

10.1158/1557-3265.sabcs25-gs3-01 Get It

Abstract Background: Women with a pathogenic variant in the BRCA1 or BRCA2 gene (carriers) are at a high risk of developing ovarian cancer and recommended to undergo bilateral salpingo-oophorectomy at an early age resulting in surgical menopause. Menopausal hormone therapy (MHT) is the most effective way to mitigate the adverse outcomes of early menopause; however, the safety of MHT on breast cancer risk in this population has not been established. Methods: We conducted a prospective matched analysis of MHT use following menopause (predominantly surgical) and breast cancer risk in BRCA carriers using a matched prospective analysis to emulate a randomized clinical trial. Women without a history of any cancer or bilateral mastectomy and who were enrolled in a longitudinal study with detailed data collection were eligible for inclusion. Women who initiated MHT (exposed) after menopause were matched one-to-one to women who had not initiated MHT (unexposed) by gene, year of birth, and age at menopause, resulting in 676 matched pairs. Cox proportional hazards regression to estimate the hazard ratios (HR) and 95%CIs (CI) of incident breast cancer associated with MHT use. Results: After a mean follow-up of 5.6 years from the date of first MHT use in the exposed woman, there were 87 incident breast cancer cases in the exposed group (12·9%) and 128 cases in the unexposed group (18·9%) (P = 0·002). Compared to their unexposed match, women who used estrogen (E) experienced a significant decrease in the risk of breast cancer (HR = 0·37; 95%: CI 0·24-0·57). There was no protective (or adverse) effect associated with the use of E plus progestogen (E+P) (HR = 0·94; 95%CI 0·54-1·63), with progestogen alone (P) (HR = 1·14; 95%CI: 0·21-6·22) or with tibolone (HR = 0·57; 95%CI: 0·19-1·69). There were no diagnoses of breast cancer in the 43 women who used a CEE + bazedoxifene. Findings were similar for carriers of either gene mutation. Conclusion: To our knowledge, this represents the largest prospective report of MHT use and breast cancer risk in BRCA1 and BRCA2 carriers. Our findings showed no increase in the risk of breast cancer with the use of MHT, irrespective of gene mutation or formulation. These findings provide an evidence-based approach for the management of women at high-risk of breast cancer who are facing the acute and chronic effects of early surgical menopause. The safe use of MHT by BRCA carriers will continue to be an important research topic as formulations continue to evolve. Citation Format: J. Kotsopoulos, M. Seca, G. Jacek, T. Huzarski, P. Møller, R. H. Kim, C. Singer, B. Karlan, A. Aeilts, T. Ramon y Cajal, T. Pal, A. Eisen, L. Bordeleau, W. Foulkes, N. Tung, F. Couch, S. Neuhausen, D. Zakalik, C. Cybulski, O. Olopade, K. Metcalfe, R. Fruscio, P. Sun, J. Lubinski, S. Narod, Hereditary Breast Cancer Clinical Study Group. Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2 [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS3-01.
Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia
Lee, Jae Woong , Sun, Ruifeng , Kume, Kohei , Robinson, Mark E. , Cheng, Zhangliang, Cosgun, Kadriye Nehir , Ma, Ning , Hurtz, Christian , Geng, Huimin , Luger, S. M., MR, Litzow, Paietta, E, Vaidehi, Nagarajan , Müschen, Markus, Luger, Selina M. , Geng, Huimin , Lee, Jaewoong , Luger, Selina M , Litzow, Mark R. , Chen, Jianjun , Vaidehi, Nagarajan , Müschen, Markus , Müschen, Markus

Mayo Clinic

Science Signaling | February 10, 2026 | Volume: 19 | Issue: 924 | Pages: No page available

10.1126/scisignal.adw5054 | PMID 41666265 Get It

CD25 is a subunit of the interleukin-2 (IL-2) receptor on T cells and natural killer (NK) cells. Acute leukemias with oncogenic tyrosine kinases often include CD25 + leukemia subpopulations, which portend poor clinical outcomes for patients; however, acute leukemia cells do not respond to IL-2. Here, we identified CD25 and its phosphorylation by protein kinase Cδ (PKCδ) as central elements of a feedback loop that stabilized fluctuations in oncogenic tyrosine kinase signaling in acute lymphoblastic and myeloid leukemia. Genetic ablation of CD25 in murine and patient-derived xenograft (PDX) models of acute leukemias reduced clonal fitness, colony formation, and leukemia-initiation capacity in serial transplant recipients. Oncogenic tyrosine kinase signaling in leukemia cells stimulated NF-κB–mediated CD25 expression, whereas PKCδ-mediated phosphorylation of CD25 suppressed oncogenic tyrosine kinase signaling through inhibitory phosphatases, such as PTPN6. Interactome analyses and mass spectrometry–based global phosphoproteomic analyses showed that CD25 deletion abolished the phosphatase activity of PTPN6, resulting in enhanced activation of tyrosine kinases and NF-κB. Four injections of a CD25 antibody-drug conjugate induced complete remission in mice transplanted with PDX refractory leukemia. These findings highlight the dependency of tyrosine kinase–driven leukemias on robust feedback control and the role of PKCδ and CD25 in assembling its components.
High NKAP expression predicts poor prognosis of breast cancer patients
Li, Yonghao , Zheng, Shu , Sun, Chenyu, Lowe, Scott, Bentley, Rachel, Li, Yaru , King, Bethany, Chen, Shuya, Zhou, Qin, Zhang, Mei , Bentley, Rachel

Mayo Clinic

Medicine | February 6, 2026 | Volume: 105 | Issue: 6 | Pages: e47497

10.1097/md.0000000000047497 | PMID 41650063 Get It

NF-κB activating protein (NKAP) plays important roles in various cancers, including breast cancer. However, its expression and prognosis value in breast cancer remains uncertain. Gene expression profiling interactive analysis, Human protein atlas database, and University of Alabama at Birmingham Cancer data analysis portal database were used to predict the expression and prognostic value of NKAP in breast cancer. Immunohistochemistry, quantitative real time polymerase chain reaction (qRT-PCR) and western blot were performed to detect NKAP expression. The effects of NKAP on cell proliferation, migration and drug sensitivity were investigated in MDA-MB-231 and SK-BR-3 cells. NKAP protein expression differed in breast cancer tissues and paraneoplastic tissues based on the cancer genome atlas data. The high NKAP expression was significantly correlated with a poor prognosis in breast cancer patients. The results of immunohistochemistry, western blot assay, and qRT-PCR proved that NKAP was highly expressed in breast cancer tissues compared with paraneoplastic tissues. In addition, qRT-PCR results showed that high expression of NKAP was significantly correlated with the larger tumor size and higher TNM stage. Moreover, knockdown of NKAP significantly inhibited the proliferation, migration, and enhanced drug sensitivity of MDA-MB-231 and SK-BR-3 cells. NKAP is highly expressed in breast cancer tissues, and its high expression is closely associated with poor prognosis. NKAP also promotes proliferation, migration, and inhibits drug sensitivity of breast cancer cells.
Analysis of Keratoconus-Related Phenotypes in Two Pcsk1 Mouse Models
Beatty, C. H., Cai, Jingwen, Yu, Hongfang, Sun, Jiong, Heo, Yejin, Baratz, Keith H. , Patel, SI, Estes, Amy, Kuo, Anthony N., Liu, Y, Beatty, Carol, Yu, Hongfang, Heo, Yejin, Bernhisel, Ashlie

Mayo Clinic

Translational Vision Science & Technology | February 4, 2026 | Volume: 15 | Issue: 2 | Pages: 3

10.1167/tvst.15.2.3 | PMID 41636415 Get It